Advanced search
Publication Cover
Infectious Diseases Volume 52, 2020 - Issue 2
Submit an article Journal homepage
375
Views
14
CrossRef citations to date
0
Altmetric
Original Articles

High risk of activation of latent tuberculosis infection in rheumatic disease patients

Wei LongDepartment of Immunology and Rheumatology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
,
Fen CaiDepartment of Immunology and Rheumatology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
,
Xinyi WangDepartment of Immunology and Rheumatology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
,
Nan ZhengDepartment of Immunology and Rheumatology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
&
Rui WuDepartment of Immunology and Rheumatology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaCorrespondence[email protected]
Pages 80-86 | Received 22 Apr 2019, Accepted 14 Oct 2019, Published online: 26 Oct 2019

References

  • Getahun H, Matteelli A, Chaisson RE, et al. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–2135.
  • Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563–1576.
  • Ai J-W, Ruan Q-L, Liu Q-H, et al. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016;5(2):e10–e10.
  • Shea KM, Kammerer JS, Winston CA, et al. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol. 2014;179(2):216–225.
  • Selmi C, Generali E, Massarotti M, et al. New treatments for inflammatory rheumatic disease. Immunol Res. 2014;60(2–3):277–288.
  • Yang JY, Jo KW, Hong S, et al. Adequacy of initiating TNF antagonists within 3 weeks of starting latent tuberculosis infection treatment in patients with immune-mediated inflammatory diseases. Infect Dis (Lond). 2016;48(4):293–298.
  • Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55(1):19–26.
  • Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection – United States. MMWR Recomm Rep. 2010;59:1–25.
  • Chen C, Zhu T, Wang Z, et al. High latent TB infection rate and associated risk factors in the eastern China of low TB incidence. PLoS One. 2015;10(10):e0141511.
  • Houben R, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152.
  • Ahmad S. New approaches in the diagnosis and treatment of latent tuberculosis infection. Respir Res. 2010;11(1):169.
  • Balbi GGM, Machado-Ribeiro F, Marques CDL, et al. The interplay between tuberculosis and systemic lupus erythematosus. Curr Opin Rheumatol. 2018;30(4):395–402.
  • Druszczyńska M, Kowalewicz-Kulbat M, Fol M, et al. Latent M. tuberculosis infection–pathogenesis, diagnosis, treatment and prevention strategies. Pol J Microbiol. 2012;61(1):3–10.
  • Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis. 2004;84(1–2):93–101.
  • Lawrence J, Fred M, Earl Hershfield, et al. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49:1–51.
  • Yang Y, Thumboo J, Tan BH, et al. The risk of tuberculosis in SLE patients from an Asian tertiary hospital. Rheumatol Int. 2017;37(6):1027–1033.
  • Lai-Shan Tam EKL, Wong S-M, Szeto C-C. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol. 2002;31:296–300.
  • Zandman-Goddard G, Shoenfeld Y. SLE and infections. Clin Rev Allergy Immunol. 2003;25(1):29–39.
  • Lu LL, Smith MT, Yu KKQ, et al. IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure. Nat Med. 2019;25(6):977–987.
  • Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36.
  • Velayati AA. Tuberculosis in children. Int J Mycobacteriol. 2016;5:S1–S2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.